Long-term weight loss for patients with obesity proved mostly successful after taking prescription-only injectable semaglutide, the Cleveland Clinic found. Researchers at the nonprofit academic and research medical center identified key factors that impact the effectiveness of the widely popular medication.

Researchers found that patients with obesity had an average weight loss of 12.9% with semaglutide vs 5.6% with liraglutide after 1 year.

Four key factors can greatly impact how much weight people lose while taking GLP-1 drugs like Ozempic, Wegovy, Victoza, and Saxenda. Here's what to know.

Injectable prescription drugs that reduce appetite — like Ozempic, Saxenda and Mounjaro — have skyrocketed in popularity in recent years.

Many people are doing an end-run around their doctor's office, reaching out to potentially unreliable sources that promise to set them up with Wegovy, Zepbound and other weight-loss drugs.

Why fork over thousands of dollars a month for prescription weight loss jabs when store-bought supplements claim to have the same effect?

Research has shown there are plenty of perks of using a medication like Ozempic for weight loss. But, given that this is a drug, there are some potential downsides to consider, too. New research published in JAMA Network Open links GLP-1 receptor agonists—a class of medications that includes semaglutide medications like Ozempic and Wegovy—to a loss of bone density.

When it comes to berberine vs. Ozempic, there are a lot of differences. The supplement actually doesn’t have much in common